Search Results - "Gaudin, A F"

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis by Cotté, F.-E, Fardellone, P, Mercier, F, Gaudin, A.-F, Roux, C

“…Summary This primary care database survey evaluated whether osteoporotic women treated with bisphosphonates were more adherent to monthly than to weekly…”
Get full text

Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021 by Grumberg, V., Cotté, F.-E., Giroux-Leprieur, E., Gaudin, A.-F., Lebbé, C., Borget, I.

“…In France, the potential benefit of new treatments is initially evaluated by the Haute Autorité de Santé to determine reimbursement and pricing, but rarely…”
Get full text

Real-world outcomes and costs in patients with recurrent or metastatic squamous cell carcinoma of the head and neck by Lafuma, A., Cotté, F.-E., Le Tourneau, C., Emery, C., Gaudin, A.-F., Torreton, E., Gourmelen, J., Bonastre, J.

Get full text

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial by Branchoux, S., Sofeu, C.L., Gaudin, A.-F., Kurt, M., Moshyk, A., Italiano, A., Bellera, C., Rondeau, V.

“…Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigated TNT-D…”
Get full text

Management of lung cancer patients' quality of life in clinical practice: a Delphi study by Westeel, V., Bourdon, M., Cortot, A.B., Debieuvre, D., Toffart, A.-C., Acquadro, M., Arnould, B., Lambert, J., Cotte, F.-E., Gaudin, A.-F., Lemasson, H.

“…The assessment of health-related quality of life (HRQoL) has seen exponential growth in oncology clinical trials. However, the measurement of HRQoL has yet to…”
Get full text

Prevalence and clinical characteristics of migraine in France by HENRY, P, AURAY, J. P, GAUDIN, A. F, DARTIGUES, J. F, DURU, G, LANTERI-MINET, M, LUCAS, C, PRADALIER, A, CHAZOT, G, EL HASNAOUI, A

“…To determine the prevalence and clinical features of migraine and related headache types in France. The authors recruited a population of subjects with…”
Get full text

Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women by Breuil, V., Cortet, B., Cotté, F.-E., Arnould, B., Dias-Barbosa, C., Gaudin, A.-F., Regnault, A., Roborel de Climens, A., Legrand, E.

“…Summary We developed and validated a specific 12-item questionnaire to evaluate adherence to oral antiresorptive medication by post-menopausal osteoporotic…”
Get full text

Estimating the cost-effectiveness of stroke units in France compared with conventional care by LAUNOIS, R, GIROUD, M, MEGNIGBETO, A. C, LE LAY, K, PRESENTE, G, MAHAGNE, M. H, DURAND, I, GAUDIN, A. F

“…The incidence of stroke in France is estimated at between 120 000 and 150 000 cases per year. This modeling study assessed the clinical and economic benefits…”
Get full text

The burden cost of French patients suffering from irritable bowel syndrome by Le Pen, C., Ruszniewski, P., Gaudin, A.-F., Amouretti, M., Bommelaer, G., Frexinos, J., Poynard, T., Maurel, F., Priol, G., Bertin, C.

“…Background: The impact of irritable bowel syndrome (IBS) on health-care resource use in France is evaluated, and explanatory variables determined. Methods: A…”
Get full text

Use and misuse of triptans in France: data from the GRIM2000 population survey by Lucas, C, Auray, J-P, Gaudin, A-F, Dartigues, J-F, Duru, G, Henry, P, Lantéri-Minet, M, Pradalier, A, Chazot, G, El Hasnaoui, A

“…The extent and nature of triptan use for headache relief has been evaluated in a large epidemiological survey in the French general population. Over 25 000…”
Get more information

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin by Lanitis, T, Cotté, F E, Gaudin, A F, Kachaner, I, Kongnakorn, T, Durand-Zaleski, I

“…To conduct an economic evaluation of the currently prescribed treatments for stroke prevention in patients with non-valvular atrial fibrillation (NVAF)…”
Get more information

P0747 : Health related quality of life and utility values in chronic hepatitis C patients: A cross-sectional study in France, the Uk and Germany by Pol, S, Chevalier, J, Branchoux, S, Perry, R, Milligan, G, Gaudin, A.-F

Get full text

Prevalence and comorbidity of psychiatric disorders in the French general population by Lépine, J-P, Gasquet, I, Kovess, V, Arbabzadeh-Bouchez, S, Nègre-Pagès, L, Nachbaur, G, Gaudin, A-F

“…ESEMeD is the first international epidemiological study using a random sampling method that has allowed the prevalence of psychiatric disorders in France to be…”
Get more information

Two methods of estimating health costs linked to alcoholism in France (with a note on social costs) by Reynaud, M., Gaudin-Colombel, A. F., Le Pen, C.

“…— The health costs of alcohol-related problems in France were estimated using two cost evaluation approaches: (1) estimate based on the proportion of cases…”
Get full text

1752P Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021 by Borget, I., Cotté, F-E., Giroux-Leprieur, E., Gaudin, A-F., Lebbe, C., Grumberg, V.

Get full text

Prevalence and description of chronic daily headache in the general population in France by Lantéri-Minet, Michel, Auray, Jean-Paul, El Hasnaoui, Abdelkader, Dartigues, Jean-François, Duru, Gérard, Henry, Patrick, Lucas, Christian, Pradalier, André, Chazot, Guy, Gaudin, Anne-Françoise

“…The objective of this study was to describe the epidemiology, clinical presentation and consequences of chronic daily headache (CDH) in France. A…”
Get full text

1330P Organizational impact of immune-checkpoint inhibitors in advanced cancers in France: Final analysis by Borget, I., Chouaid, C., Cotté, F-E., Gaudin, A-F., Grumberg, V.

Get full text

1753P Cost-effectiveness (CE) of nivolumab (NIVO) as adjuvant treatment of muscle invasive urothelial carcinoma at high risk of recurrence (MIUC-HR) in France by Negrier, M.S., Colrat, F.P., Bonastre, J., Chamielec, C., Teitsson, S., Knight, C., Ni, L., Chevalier, J., Gaudin, A-F., Roupret, M., Branchoux, S.

Get full text

Oncologists’ consideration of health-related quality of life in clinical practice for immune-checkpoint inhibitors-treated patients: An online patients community research by Wilczynski, O., Boisbouvier, A., Radoszycki, L., Cotté, F.-E., Gaudin, A.-F., Lemasson, H.

Get full text

101P Nivolumab outcomes in interstitial lung disease patients with advanced non-small cell lung cancer in French real-world setting by Assie, J-B., Chouaid, C., Nunes, H., Reynaud, D., Gaudin, A-F., Grumberg, V., Jolivel, R., Jouaneton, B., Cotté, F-E., Duchemann, B.

Get full text